Acadian Increases Stake in Aclaris Therapeutics, Inc. (ACRS) as Phase 2a Data Gains Spotlight [Yahoo! Finance]
Aclaris Therapeutics, Inc. (ACRS)
Last aclaris therapeutics, inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
aclaristx.com
Company Research
Source: Yahoo! Finance
Form 13F filing with the SEC, Acadian Asset Management LLC expanded its holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) by 25.9% in the first quarter. With the purchase of 451,044 shares, the investment manager now owns 2,195,191 shares of the company's stock, representing an ownership stake of 2.03%. Despite the company's history of failures, Aclaris Therapeutics, Inc. (NASDAQ:ACRS) appears to be on the right track for future success. Just recently, the company announced that new data from its Phase 2a trial of ATI-2138 for atopic dermatitis will be highlighted as a late-breaking abstract at the 2025 EADV Congress in Paris. ATI-2138, a leading selective oral covalent inhibitor of ITK and JAK3, serves as a solution for moderate to severe atopic dermatitis. The session, delivered by Dr. Jessica Beaziz-Tordjman, covered the drug's effectiveness in treating the condition. Aclaris Therapeutics, Inc. (NASDAQ:ACRS) is a Pennsylvania-based clinical-stage biopharmaceutical company
Show less
Read more
Impact Snapshot
Event Time:
ACRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACRS alerts
High impacting Aclaris Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ACRS
News
- Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswire
- Aclaris Therapeutics (NASDAQ:ACRS) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Aclaris Therapeutics (NASDAQ:ACRS) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswire
ACRS
Earnings
- 11/6/25 - Beat
ACRS
Analyst Actions
- 10/20/25 - HC Wainwright
ACRS
Sec Filings
- 12/4/25 - Form 4
- 11/13/25 - Form SCHEDULE
- 11/6/25 - Form 10-Q
- ACRS's page on the SEC website